Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial-Reference-Cited by-同舟云学术

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

Published:2018-02-22 Issue:6 Volume:7 Page:e1433516
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Patel Poulam M.¹,Ottensmeier Christian H.²,Mulatero Clive³,Lorigan Paul⁴,Plummer Ruth⁵^ORCID,Pandha Hardev⁶,Elsheikh Somaia⁷,Hadjimichael Efthymios⁷,Villasanti Naty⁷,Adams Sally E.⁸,Cunnell Michelle¹,Metheringham Rachael L.⁸,Brentville Victoria A.⁸,Machado Lee⁸^ORCID,Daniels Ian⁸^ORCID,Gijon Mohamed⁸^ORCID,Hannaman Drew⁹,Durrant Lindy G.¹⁸

Affiliation:

1. Academic Department of Clinical Oncology, Division of Cancer & Stem Cells, University of Nottingham, Nottingham, UK

2. Southampton Experimental Cancer Medicine Centre and Southampton University Hospitals, Faculty of Medicine, Southampton, UK

3. St James's University Hospital, Leeds, UK

4. Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK

5. Northern Institute for Cancer Research, Medical School, University of Newcastle-upon-Tyne and Wear, UK

6. Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, UK

7. University of Nottingham, School of Medicine Queen's Medical Centre, Nottingham, UK

8. Scancell Limited, Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK

9. Ichor Medical Systems, Inc., San Diego, CA, USA

Funder

Department of Clinical Oncology

University of Nottingham

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1433516

Reference41 articles.

1. Nivolumab plus Ipilimumab in Advanced Melanoma

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Pembrolizumab versus Ipilimumab in Advanced Melanoma

4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

5. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2’Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model;2024-08-20

2. TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors;Cancer Immunology, Immunotherapy;2024-07-02

3. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies;Journal of Ovarian Research;2024-01-16

4. Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2’Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model;2023-08-14

5. What do cancer-specific T cells ‘see’?;Discovery Immunology;2022-12-06